Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

696 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T. Mabuchi S, et al. Among authors: nishio y. Mol Cancer Ther. 2010 Aug;9(8):2411-22. doi: 10.1158/1535-7163.MCT-10-0169. Epub 2010 Jul 27. Mol Cancer Ther. 2010. PMID: 20663925 Free PMC article.
Inhibition of inhibitor of nuclear factor-kappaB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, Kawagoe J, Takahashi K, Yada-Hashimoto N, Seino-Noda H, Sakata M, Motoyama T, Kurachi H, Testa JR, Tasaka K, Murata Y. Mabuchi S, et al. Among authors: nishio y. Clin Cancer Res. 2004 Nov 15;10(22):7645-54. doi: 10.1158/1078-0432.CCR-04-0958. Clin Cancer Res. 2004. PMID: 15569997
Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin.
Mabuchi S, Ohmichi M, Kimura A, Ikebuchi Y, Hisamoto K, Arimoto-Ishida E, Nishio Y, Takahashi K, Tasaka K, Murata Y. Mabuchi S, et al. Among authors: nishio y. Endocrinology. 2004 Mar;145(3):1302-13. doi: 10.1210/en.2003-0709. Epub 2003 Nov 26. Endocrinology. 2004. PMID: 14645110
Chemotherapy for endometrial carcinoma (GOGO-EM1 study): TEC (paclitaxel, epirubicin, and carboplatin) is an effective remission-induction and adjuvant therapy.
Egawa-Takata T, Ueda Y, Kuragaki C, Miyake T, Miyatake T, Fujita M, Yoshino K, Nakashima R, Okazawa M, Tsutsui T, Morishige K, Kimura T, Yamasaki M, Nishizaki T, Nagamatsu M, Ito K, Asada M, Ogita K, Wakimoto A, Yamamoto T, Nishio Y, Enomoto T. Egawa-Takata T, et al. Among authors: nishio y. Cancer Chemother Pharmacol. 2011 Dec;68(6):1603-10. doi: 10.1007/s00280-011-1638-4. Epub 2011 May 17. Cancer Chemother Pharmacol. 2011. PMID: 21584840 Clinical Trial.
Efficacy of raloxifene hydrochloride for the prevention of health care problems in patients who undergo surgery for endometrial cancer: a multicenter randomized clinical trial.
Nakamura K, Sawada K, Sugiyama M, Mabuchi S, Hisamatsu T, Nishio Y, Ito K, Kimura T, Kamiura S, Morishige K. Nakamura K, et al. Among authors: nishio y. Int J Gynecol Cancer. 2015 Feb;25(2):288-95. doi: 10.1097/IGC.0000000000000333. Int J Gynecol Cancer. 2015. PMID: 25569817 Clinical Trial.
696 results